A Phase 2 interventional study of eftilagimod alpha and pembrolizumab (KEYTRUDA®) in NSCLC and HNSCC, sponsored by Immutep S.A.S.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-22.
Sponsored by Immutep S.A.S. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States — 217 open to participants now, 347 under way, 28 of them phase 3. Squamous Cell Carcinoma of Head and Neck · United States.
Among the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States, this one is the 146th largest by enrollment of the 993 interventional ones that give a count, is one of 71 that started in 2019, is one of 359 in phase 2, and was the 556th registered.
2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.
Browse Squamous Cell Carcinoma of Head and Neck studies →217 of the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18+
University of Miami · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
Mayo Clinic · Sites in United States
Ages 18+
West Virginia University · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,099 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 519 · Phase 2 528 · Phase 3 83 · Phase 4 4
First in 1988; this study’s year is marked. 71 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 187 is above the median of 48 across 1,653 interventional studies indexed under Squamous Cell Carcinoma of Head and Neck.
Median enrollment 41 across the 993 interventional studies, 130 across the 63 observational. Of the 690 that completed or were terminated, 288 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
420 of 1,099 have an industry lead sponsor. The 10 most frequent:
Immutep S.A.S. is the lead sponsor of 11 studies on the registry; none are open to participants now.
Immutep S.A.S. has 2 studies filed under Squamous Cell Carcinoma of Head and Neck — fewer than ten, so there is no comparison to draw.
107 of the studies in Squamous Cell Carcinoma of Head and Neck with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06998069Phase 3Brown UniversityHead and Neck Cancer Study Project in the Geriatric Population | 2026-12-01 |
| NCT06064877Phase 3AVEO Pharmaceuticals, Inc.A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma | 2027-08 |
| NCT04965792Dana-Farber Cancer InstitutePost-treatment Surveillance in HPV+ Oropharyngeal SCC | 2026-11 |
| NCT05600842University of California, IrvineDe-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx | 2026-11 |
| NCT02955290Roswell Park Cancer InstituteCIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer | 2026-11-25 |
Add all 107 to your calendar (.ics) → With an account.
Among the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Evaluate the safety and efficacy of the combination of eftilagimod alpha with pembrolizumab in non-small cell lung carcinoma and head and neck carcinoma patients.
Up to 187 patients will be recruited in the TACTI-002 (Two ACTive Immunotherapies) Phase II study which will take place across approximately 22 study centres in the U.S., Europe and Australia. It will evaluate the safety and efficacy of the combination of eftilagimod alpha with pembrolizumab in patients with advanced or metastatic non-small cell lung carcinoma or head and neck carcinoma. It will be a Simon's two-stage, non-comparative, open-label, single-arm, multicentre clinical study. Patients participating in the trial will be given the combination treatment for 12 months using a 30 mg s.c. eftilagimod alpha dosing every 2 or 3 weeks.
Main Inclusion Criteria:
Part A (, PD-X naïve NSCLC): - or cytologically-confirmed diagnosis of non-small cell lung carcinoma stage IIIB not amenable to curative treatment or stage IV not amenable to EGFR/ALK based therapy, treatment naïve for systemic therapy given for advanced/ disease (previous palliative radiotherapy for advanced/metastatic disease acceptable)
Part B (2nd line, PD-X NSCLC): histologically- or cytologically-confirmed diagnosis of NSCLC after failure of first-line treatment (for metastatic disease) with at least 2 cycles of any /PD-L1 containing based therapy (e.g. nivolumab, pembrolizumab, avelumab, durvalumab, etc.) alone, or in combination with any other immunotherapeutic or chemotherapy given as part of first-line treatment.
Part C (2nd line PD-X naive HNSCC): Histologically- or cytologically-confirmed recurrent disease not amenable to curative treatment with local or systemic therapy, or metastatic (disseminated) HNSCC of the oral cavity, oropharynx, hypopharynx, and larynx that is considered incurable by local therapies after failure of prior platinum-based therapy.
Main Exclusion Criteria:
For part A (1st line, PD-X naïve NSCLC):
For Part B (2nd line, PD-X refractory NSCLC):
For Part C (2nd line PD-X naive HNSCC):
Has received prior chemotherapy, anti-cancer monoclonal antibody, major surgery, another systemic cancer therapy or has participated in a study of an agent or has used an investigational device within 4 weeks prior to cycle 1 day 1.
Note: Patients must have recovered from all AEs due to previous therapies to ≤Grade 1 or baseline. Patients with ≤Grade 2 neuropathy, alopecia and elevated transaminases in case of liver metastases may be eligible. If patient received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment. Participants who have entered the follow-up phase of an investigational study may participate as long as it has been 4 weeks after the last dose of the previous investigational agent.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
eftilagimod alpha: 30 mg every 2 weeks for the first 8 cycles (1 cycle = 3 weeks) and every 3 weeks thereafter (starting cycle 9). pembrolizumab (KEYTRUDA®): 200 mg every 3 weeks.
Drug: eftilagimod alpha · Drug: pembrolizumab (KEYTRUDA®)
eftilagimod alpha: 30 mg every 2 weeks for the first 8 cycles (1 cycle = 3 weeks) and every 3 weeks thereafter (starting cycle 9). pembrolizumab (KEYTRUDA®): 200 mg every 3 weeks.
Drug: eftilagimod alpha · Drug: pembrolizumab (KEYTRUDA®)
eftilagimod alpha: 30 mg every 2 weeks for the first 8 cycles (1 cycle = 3 weeks) and every 3 weeks thereafter (starting cycle 9). pembrolizumab (KEYTRUDA®): 200 mg every 3 weeks.
Drug: eftilagimod alpha · Drug: pembrolizumab (KEYTRUDA®)
APC activator, MHC II agonist, LAG-3 fusion protein
Also known as: IMP321, efti, eftilagimod alfa
anti-PD-1 antibody
Also known as: MK-3475
Evaluation of Objective Response Rate (ORR) According to iRECIST (Unconfirmed)
ORR was defined as the percentage of participants for each dose level whose best overall response is rated as iCR or iPR per immune Response Evaluation Criteria In Solid Tumors (iRECIST) for target lesions and assessed by CT or MRI. iCR was defined as disappearance of all target and non-target lesions and any pathological lymph nodes must be \<10 mm in the short axis. iPR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.
Time frame: Data collected from screening until time of disease progression, death, lost to follow up, study discontinuation, whichever occurs first, assessed up to approximately 68 months
Evaluation of Objective Response Rate (ORR) According to iRECIST (Confirmed)
ORR was defined as the percentage of participants for each dose level whose best overall response is rated as iCR or iPR per immune Response Evaluation Criteria In Solid Tumors (iRECIST) for target lesions and assessed by CT or MRI. iCR was defined as disappearance of all target and non-target lesions and any pathological lymph nodes must be \<10 mm in the short axis. iPR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.
Time frame: Data collected from screening until time of disease progression, death, lost to follow up, study discontinuation, whichever occurs first, assessed up to approximately 68 months
Duration of (Serious) Adverse Events
Time frame: up to 27 months
Frequency of (Serious) Adverse Events
Time frame: up to 27 months
Severity of (Serious) Adverse Events
Time frame: up to 27 months
Time to Responses According to iRECIST and RECIST 1.1
Time frame: up to 68 months
Duration of Responses According to iRECIST and RECIST 1.1
Time frame: up to 68 months
Response Rate According to RECIST 1.1
Time frame: up to 68 months
Disease Control Rate According to iRECIST and RECIST 1.1
Time frame: up to 68 months
Progression Free Survival (PFS)
Time frame: up to 68 months
Overall Survival (OS)
Time frame: up to 68 months
Occurrence of Eftilagimod Alpha-specific Antibodies (ADA)
Time frame: up to 24 month
Plasma Concentration Time Profile of Eftilagimod Alpha
Time frame: up to 24 month
The first ICF for the study was signed on February 21, 2019. Recruitment ended on November 30, 2021. 18 sites in 6 countries. Number of sites per country: Australia (2), Poland (1), Spain (8), UK (3), Ukraine (2) and US (2).
| Milestone | 1st Line NSCLC | 2nd Line NSCLC | 2nd Line HNSCC |
|---|---|---|---|
| Started | 114 | 36 | 37 |
| Completed | 22 | 2 | 4 |
| Not completed | 92 | 34 | 33 |
ORR was defined as the percentage of participants for each dose level whose best overall response is rated as iCR or iPR per immune Response Evaluation Criteria In Solid Tumors (iRECIST) for target lesions and assessed by CT or MRI. iCR was defined as disappearance of all target and non-target lesions and any pathological lymph nodes must be \<10 mm in the short axis. iPR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.
| Participants | 1st Line NSCLC | 2nd Line NSCLC | HNSCC |
|---|---|---|---|
| Evaluation of Objective Response Rate (ORR) According to iRECIST (Unconfirmed) | 46 | 3 | 11 |
ORR was defined as the percentage of participants for each dose level whose best overall response is rated as iCR or iPR per immune Response Evaluation Criteria In Solid Tumors (iRECIST) for target lesions and assessed by CT or MRI. iCR was defined as disappearance of all target and non-target lesions and any pathological lymph nodes must be \<10 mm in the short axis. iPR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.
| Participants | 1st Line NSCLC | 2nd Line NSCLC | HNSCC |
|---|---|---|---|
| Evaluation of Objective Response Rate (ORR) According to iRECIST (Confirmed) | 40 | 3 | 10 |
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Collected over Up to 27 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 1st Line NSCLC | 84/114 (73.7%) | 54/114 (47.4%) | 114/114 (100%) |
| 2nd Line NSCLC | 30/36 (83.3%) | 9/36 (25%) | 35/36 (97.2%) |
| 2nd Line HNSCC | 31/37 (83.8%) | 20/37 (54.1%) | 36/37 (97.3%) |
| Event | 1st Line NSCLC | 2nd Line NSCLC | 2nd Line HNSCC |
|---|---|---|---|
| DyspneaRespiratory, thoracic and mediastinal disorders | 8/114 | 0/36 | 0/37 |
| Tumor painNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/114 | 1/36 | 2/37 |
| Urinary tract infectionInfections and infestations | 0/114 | 0/36 | 2/37 |
| HypercalcemiaMetabolism and nutrition disorders | 0/114 | 0/36 | 2/37 |
| SyncopeNervous system disorders | 0/114 | 0/36 | 2/37 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/114 | 0/36 | 2/37 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 4/114 | 0/36 | 1/37 |
| HemoptysisRespiratory, thoracic and mediastinal disorders | 4/114 | 0/36 | 0/37 |
| Lower respiratory tract infectionInfections and infestations | 2/114 | 1/36 | 1/37 |
| PneumoniaInfections and infestations | 3/114 | 1/36 | 1/37 |
| Event | 1st Line NSCLC | 2nd Line NSCLC | 2nd Line HNSCC |
|---|---|---|---|
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 39/114 | 13/36 | 3/37 |
| Decreased appetiteMetabolism and nutrition disorders | 30/114 | 13/36 | 4/37 |
| AstheniaGeneral disorders | 39/114 | 8/36 | 8/37 |
| CoughRespiratory, thoracic and mediastinal disorders | 34/114 | 11/36 | 7/37 |
| AnaemiaBlood and lymphatic system disorders | 28/114 | 1/36 | 7/37 |
| PruritusSkin and subcutaneous tissue disorders | 27/114 | 5/36 | 4/37 |
| FatigueGeneral disorders | 26/114 | 8/36 | 6/37 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 19/114 | 7/36 | 4/37 |
| Weight decreasedInvestigations | 6/114 | 6/36 | 7/37 |
| HypothyroidismEndocrine disorders | 11/114 | 1/36 | 7/37 |
| Age, Categorical(Participants) | 1st Line NSCLC | 2nd Line NSCLC | HNSCC | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 39 | 15 | 20 | 74 |
| >=65 years | 75 | 21 | 17 | 113 |
| Age, Continuous(Years) | 1st Line NSCLC | 2nd Line NSCLC | HNSCC | Total |
|---|---|---|---|---|
| Median | 67 (44 to 85) | 67 (46 to 84) | 63 (48 to 84) | 67 (44 to 85) |
| Sex: Female, Male(Participants) | 1st Line NSCLC | 2nd Line NSCLC | HNSCC | Total |
|---|---|---|---|---|
| Female | 30 | 14 | 4 | 48 |
| Male | 84 | 22 | 33 | 139 |
| Race (NIH/OMB)(Participants) | 1st Line NSCLC | 2nd Line NSCLC | HNSCC | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 2 | 0 | 4 |
| White | 109 | 34 | 35 | 178 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 0 | 1 | 3 |
| Ethnicity (NIH/OMB)(Participants) | 1st Line NSCLC | 2nd Line NSCLC | HNSCC | Total |
|---|---|---|---|---|
| Hispanic or Latino | 5 | 4 | 1 | 10 |
| Not Hispanic or Latino | 109 | 32 | 36 | 177 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Smoking history(Participants) | 1st Line NSCLC | 2nd Line NSCLC | HNSCC | Total |
|---|---|---|---|---|
| Non-smoker | 6 | 5 | 5 | 16 |
| Ex- or current smoker | 108 | 31 | 32 | 171 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2019 to primary completion in Jun 2022, 39 months.
Results were first posted in Dec 2024, 2 years 6 months after primary completion.
Of 68 industry-sponsored phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 60. This study's 39 months is close to that.
Counting every sponsor, half of 366 studies reached it within 53 months; a quarter within 35 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Etilagimod alpha
Squamous Cell Carcinoma of Head and Neck →
Immutep S.A.S.